February 09, 2023

Abbvie puts (some) numbers on expected Humira erosion

February 02, 2023

Roche adds to the lung fibrosis disappointment

February 01, 2023

Novartis trims its pipeline

Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.

May 26, 2022

Medtronic downsizes, but not sizeably

March 23, 2022

Breakeven still distant for Oxford Nanopore

March 11, 2022

Another strike for biotech: China

Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.

February 24, 2022

Biomarin’s Voxzogo disappoints in youngsters

February 10, 2022

Astra bake-off cooks up a new inhaled Jak

February 09, 2022

Pfizer’s $100bn question

Record guidance disappoints, so talk once again turns to deals.